Ask AI
Advances from EHA and ICML 2025

CME

Congress to Clinic: Expert Perspectives on Therapeutic Advances and Practice Changing Data Emerging From the 2025 EHA and ICML Congresses

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: September 25, 2025

Expiration: March 24, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Max S. Topp, MD, and Pier Luigi Zinzani, MD, PhD, provide an overview of recent advances and practice-changing data that emerged from the 2025 European Hematology Association (EHA) and International Conference on Malignant Lymphoma (ICML) congresses.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Please note that Clinical Care Options plans to measure the educational impact of this activity. Some questions are asked twice: once at the beginning of the activity and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your individual responses will not be shared. Thank you in advance for helping us assess the impact of this education.

Before continuing with this educational activity, please take a moment to answer the following questions.

Which of the following accurately describes the mechanism of action of the investigational agent surovatamig?

A 75-year-old man (Eastern Cooperative Oncology Group performance status 1) presents with newly diagnosed mantle cell lymphoma (MCL) with high-risk biology (Ki-67 40%, TP53 mutation). Which of the following treatments would you recommend for this patient if their goal was to optimize their outcomes?

Did the POLARGO trial of polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin (R-GemOx) compared with R-GemOx in transplant-ineligible patients with R/R DLBCL show significant improvement in response, PFS, or OS, or were the results similar between treatment arms?

How many patients with lymphomas and leukemias do you provide care for in a typical month?